BIONET Corp. (TPEX:1784)

Market Cap	4.34B
Revenue (ttm)	1.22B
Net Income (ttm)	83.70M
Shares Out	50.72M
EPS (ttm)	1.65
PE Ratio	51.82
Forward PE	n/a
Dividend	0.66 (0.77%)
Ex-Dividend Date	Sep 19, 2024

Volume	122,714
Average Volume	319,399
Open	85.10
Previous Close	85.50
Day's Range	84.20 - 86.00
52-Week Range	52.12 - 162.01
Beta	0.59
RSI	52.78
Earnings Date	Mar 28, 2025

About BIONET

BIONET Corp. provides cell therapy services in Taiwan and internationally. The company offers stem cell banking services, including stem cell storage, mesenchymal stem cell storage, dental stem cell storage, adipose stem cell, and peripheral blood stem cells and immune cells; and genetic testing services. It also provides stem anti-aging and ANIKINE series products; and Exosome, a novel cell-free therapy. In addition, the company offers regenerative medicine, analytical testing, clinical and preclinical research, and commercialized cell-derived...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1989
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 1784

Financial Performance

In 2024, BIONET's revenue was 1.22 billion, an increase of 8.40% compared to the previous year's 1.13 billion. Earnings were 83.70 million, an increase of 6.76%.